Myocardial Contractile Dysfunction Is Present without Histopathology in a Mouse Model of Limb-Girdle Muscular Dystrophy-2F and Is Prevented after Claudin-5 Virotherapy
Open Access
- 6 December 2016
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 7, 539
Abstract
Mutations in several members of the dystrophin glycoprotein complex lead to skeletal and cardiomyopathies. Cardiac care for these muscular dystrophies consists of management of symptoms with standard heart medications after detection of reduced whole heart function. Recent evidence from both Duchenne muscular dystrophy patients and animal models suggests that myocardial dysfunction is present before myocardial damage or deficiencies in whole heart function, and that treatment prior to heart failure symptoms may be beneficial. To determine whether this same early myocardial dysfunction is present in other muscular dystrophy cardiomyopathies, we conducted a physiological assessment of cardiac function at the tissue level in the δ-sarcoglycan null mouse model (Sgcd-/-) of Limb-girdle muscular dystrophy type 2F. Baseline cardiac contractile force measurements using ex vivo intact linear muscle preparations, were severely depressed in these mice without the presence of histopathology. Virotherapy with claudin-5 prevents the onset of cardiomyopathy in another muscular dystrophy model. After virotherapy with claudin-5, the cardiac contractile force deficits in Sgcd-/- mice are no longer significant. These studies suggest that screening Limb-girdle muscular dystrophy patients using methods that detect earlier functional changes may provide a longer therapeutic window for cardiac care.Keywords
Funding Information
- Muscular Dystrophy Association
- American Heart Association
This publication has 49 references indexed in Scilit:
- Early Treatment With Lisinopril and Spironolactone Preserves Cardiac and Skeletal Muscle in Duchenne Muscular Dystrophy MiceCirculation, 2011
- Distinct pathophysiological mechanisms of cardiomyopathy in hearts lacking dystrophin or the sarcoglycan complexThe FASEB Journal, 2011
- Lengthening-contractions in isolated myocardium impact force development and worsen cardiac contractile function in the mdx mouse model of muscular dystrophyJournal of Applied Physiology, 2011
- Cardiac Involvement in Patients With Muscular DystrophiesCirculation: Cardiovascular Imaging, 2011
- Distinct genetic regions modify specific muscle groups in muscular dystrophyPhysiological Genomics, 2011
- Magnetic resonance imaging assessment of cardiac dysfunction in δ-sarcoglycan null miceNeuromuscular Disorders, 2011
- Kinetics of cardiac muscle contraction and relaxation are linked and determined by properties of the cardiac sarcomereAmerican Journal of Physiology-Heart and Circulatory Physiology, 2010
- Circumferential Strain Analysis Identifies Strata of Cardiomyopathy in Duchenne Muscular DystrophyJACC, 2009
- Microutrophin Delivery Through rAAV6 Increases Lifespan and Improves Muscle Function in Dystrophic Dystrophin/Utrophin-deficient MiceMolecular Therapy, 2008
- Determinants of frequency-dependent contraction and relaxation of mammalian myocardiumJournal of Molecular and Cellular Cardiology, 2007